With 0.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.24 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $28.41 whereas the lowest price it dropped to was $26.57. The 52-week range on GRDN shows that it touched its highest point at $26.91 and its lowest point at $14.16 during that stretch. It currently has a 1-year price target of $27.33. Beta for the stock currently stands at 1.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRDN was up-trending over the past week, with a rise of 9.14%, but this was up by 40.23% over a month. Three-month performance surged to 30.32% while six-month performance rose 45.02%. A look at the trailing 12-month EPS for GRDN yields -1.45 with Next year EPS estimates of 1.04. For the next quarter, that number is 0.24. This implies an EPS growth rate of 154.61% for this year and 7.59% for next year.
Float and Shares Shorts:
At present, 22.73 million GRDN shares are outstanding with a float of 19.50 million shares on hand for trading. On 2025-08-15, short shares totaled 0.5 million, which was 77.99999999999999 higher than short shares on 1752537600. In addition to Mr. Fred P. Burke as the firm’s CEO, President & Director, Mr. David K. Morris serves as its CFO, Executive VP & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, GRDN reported revenue of $344334000.0 and operating income of $12580000.0. The EBITDA in the recently reported quarter was $18248000.0 and diluted EPS was $0.14.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRDN analysts setting a high price target of 28.0 and a low target of 26.0, the average target price over the next 12 months is 27.33333. Based on these targets, GRDN could drop -1.44% to reach the target high and fall by -8.48% to reach the target low. Reaching the average price target will result in a decline of -3.79% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.19362 being high and $0.19313 being low. For GRDN, this leads to a yearly average estimate of $0.19333. The surprise factor in the prior quarter was $0.22. Based on analyst estimates, the high estimate for the next quarter is $0.26 and the low estimate is $0.25. The average estimate for the next quarter is thus $0.25.
